The health testing kit developer has received $14.5m in series C round funding from investors including corporate backer Xiamen C&D.
China-based medical diagnostics equipment developer Shandong Yingsheng Biological Technology has reeled in approximately RMB100m ($14.5m) in a series C round that featured supply chain services provider Xiamen C&D, PEdaily.cn has reported.
Life science-focused venture capital firm BioVenture also took part in the round, which came after two rounds of undisclosed size that included Source Capital and SunzFund, according to China Money Network.
Founded in 2009, Yingsheng Biology develops and sells vitro diagnostic reagents and medical kits that are used to…
